Workflow. (A) Four independent YTMA471 blocks, were analyzed; each block containing one non-adjacent tumor core per patient. (B) For the CK compartment 34 cores had evaluable CK+tissue in all four YTMA blocks (marked with magenta); 22 cores had evaluable CK+ tissue in at least one block and consisted the validation set. Credit: Journal for ImmunoTherapy of Cancer (2024). DOI: 10.1136/jitc-2024-009039 Immunotherapy can be a highly effective treatment for non-small cell lung cancer (NSCLC), but some patients are resistant to the therapy or develop intolerable side effects. Now, researchers from Yale Read More